Lexeo Therapeutics (LXEO) Net Cash Flow (2022 - 2026)

Lexeo Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at $8.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 243.62% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $42.9 million (up 125.79% YoY), while the FY2025 annual figure was $28.0 million, up 132.37% from the prior year.
• Net Cash Flow came in at $8.8 million for Q1 2026 at Lexeo Therapeutics, down from $22.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $86.0 million in Q4 2023 to a low of -$122.0 million in Q4 2024.
• A 5-year average of -$1.6 million and a median of -$8.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 611.58% in 2023 and plunged 241.84% in 2024, its largest moves.
• Lexeo Therapeutics' Net Cash Flow stood at -$16.8 million in 2022, then soared by 611.58% to $86.0 million in 2023, then slumped by 241.84% to -$122.0 million in 2024, then soared by 118.04% to $22.0 million in 2025, then plunged by 60.15% to $8.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $8.8 million, $22.0 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison